Thoma Bravo announces deals in drug diversion sector; plus, generative AI in healthcare

Thoma Bravo backs medication intelligence firm Bluesight.

17 July 2023•4 mins read

[data-article-body-skeleton]{display:none!important}

JavaScript is required to read this article. Please enable it in your browser and reload the page.